J07AN01 - Tuberculosis, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the tuberculosis, live attenuated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated Mycobacterium bovis BCG (Bacillus Calmette-Guérin).
Therapeutic characteristics
The tuberculosis, live attenuated vaccine (BCG vaccine) is indicated for active immunization against against tuberculosis in individuals from the age of 6 weeks to 35 years.
It is administered as a single intradermal injection.
Metabolism and pharmacokinetics
The BCG vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). BCG-vaksine SSI.
|
|
Tradenames
BCG vaccin 
Vacuna bcg 
bcg · Vacbcg 
bcg 
bcg 
BCG-vaksine 
bcg · Szczepionka przeciwgruzlicza BCG 
Bcg 
bcg · BCG vaccin · Szczepionka przeciwgruzlicza BCG · Tuberculin 
bcg 
bcg 
bcg 
bcg · bcg Anti Tuberculosis 
Vaccines